Please note that IPD sharing statement and summary results sections will be added to the ANZCTR form in the coming months in order to comply with the updated WHO Trial Registration Data Set.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT01032291




Trial ID
NCT01032291
Ethics application status
Date submitted
14/12/2009
Date registered
14/12/2009
Date last updated
1/04/2013

Titles & IDs
Public title
A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer
Scientific title
A Phase 2, Open-Label Study To Evaluate The Efficacy And Safety Of Lenalidomide In Combination With Cetuximab In Pretreated Subjects With K-Ras Mutant Metastatic Colorectal Cancer
Secondary ID [1] 0 0
2009-012665-61
Secondary ID [2] 0 0
CC-5013-COLO-001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Colorectal Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Bowel - Back passage (rectum) or large bowel (colon)

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - cetuximab
Treatment: Drugs - lenalidomide

Experimental: lenalidomide plus cetuximab - Combination therapy of lenalidomide plus cetuximab

Experimental: lenalidomide - Single agent therapy of lenalidomide


Treatment: Drugs: cetuximab
Intravenous infusions of cetuximab (400 mg/m^2 Cycle 1 Day 1, thereafter 250 mg/m^2), administered on days 1, 8, 15 and 22 of each 28 day cycle.

Treatment: Drugs: lenalidomide
Daily oral lenalidomide 25mg on days 1 to 28 of each 28 day cycle

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Participants With Dose Limiting Toxicities (DLTs) During the First Treatment Cycle of the Safety Lead-In Period - The number of participants with DLTs determines the maximum tolerated dose of the combination therapy used in the Proof of Concept (POC) period:
If <2 of the initial 6 participants experience a DLT, then the POC will start with lenalidomide at 25 mg.
If =2 of the initial 6 participants experienced a DLT, then 6 more subjects were to be enrolled at 20 mg lenalidomide.
If <2 of the additional 6 subjects experienced a DLT, then the lenalidomide starting dose for the POC was to be 20 mg.
If =2 of the additional 6 subjects experienced a DLT, then 6 more subjects were to be enrolled at 15 mg lenalidomide.
If <2 of the additional 6 subjects experienced a DLT, then the POC was to start with lenalidomide at 15 mg.
If =2 of the additional 6 subjects experienced a DLT, the dosing for the study was to be reassessed by Celgene Corporation and the investigators.
Timepoint [1] 0 0
Up to Day 28 (Cycle 1)
Primary outcome [2] 0 0
Percentage of Participants With a Response to Treatment During the Proof of Concept Period - Tumor response was evaluated every 2 cycles beginning with Cycle 3 Day 1 and at treatment discontinuation. Response and progression were evaluated using the RECIST 1.1 criteria (Eisenhauer, 2009).
Treatment response includes both complete response and partial response.
Complete response-disappearance of all lesions
Partial response-30% decrease in the sum of diameters of target lesions from baseline
Analysis was not performed due to the early termination of the study.
Timepoint [2] 0 0
week 9 up to week 24
Secondary outcome [1] 0 0
Kaplan-Meier Estimates for Progression Free Survival (PFS) - PFS was calculated as the time from randomization to the earlier of the first documentation of progressive disease (PD), or death on study due to any cause.
Analysis was not performed due to the early termination of the study.
Timepoint [1] 0 0
up to week 24
Secondary outcome [2] 0 0
Kaplan-Meier Estimates for Duration of Response - Duration of response was defined as the time from the initial response date to progressive disease (PD) for participants who achieved an objective confirmed complete response (CR) or partial response (PR).
Analysis was not performed due to the early termination of the study.
Timepoint [2] 0 0
up to week 24
Secondary outcome [3] 0 0
Percentage of Participants With Disease Control - Known as the Disease Control Rate (DCR), participants with a complete response, partial response or stable disease contribute to the DCR.
This analysis was not performed due to the early termination of the study.
Timepoint [3] 0 0
up to week 24
Secondary outcome [4] 0 0
Kaplan-Meier Estimates for Overall Survival - Overall survival was defined as the time between randomization and death. It was intended that participants would be followed for up to 5 years following discontinuation from treatment.
Analysis was not performed due to the early termination of the study.
Timepoint [4] 0 0
up to 5.5 years
Secondary outcome [5] 0 0
Participants With Treatment-Emergent Adverse Events (TEAE) - TEAEs are any adverse event occurring or worsening on or after the first treatment of any study drug and within 28 days after the last dose of the last study drug received. Relation to study drug was determined by the investigator. Severity of AE is graded according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 4.0. Severity is a 5-point scale: 3= severe or medically significant but not life-threatening 4=life-threatening, urgent intervention required 5=death related to AE.
Timepoint [5] 0 0
up to week 28

Eligibility
Key inclusion criteria
1. Metastatic colorectal adenocarcinoma.

2. Confirmed K-RAS mutant tumor

3. Disease progression on oxaliplatin- AND irinotecan-containing regimens, with at least
one of these regimens containing bevacizumab.

4. Eastern Cooperative Oncology Group (ECOG) performance status of = 1.
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Use of chemotherapy, hormonal therapy, immunotherapy or any other cancer or
experimental treatment = 28 days prior to the first day of the first cycle.

2. Radiotherapy for up to = 30% of the bone marrow.

3. Surgery = 28 days before day 1 of the first cycle (minimally invasive interventions
for diagnostic purposes or disease staging are permitted).

4. Previous treatment with cetuximab, panitumumab, pomalidomide (CC-4047), lenalidomide
or thalidomide.

5. Untreated, symptomatic brain metastases (brain imaging not required).

6. Venous thromboembolism = 6 months before day1 of the first cycle.

7. Current congestive heart failure (classes II to IV of the New York Heart Association).

8. Myocardial infarction = 12 months before day1 of the first cycle.

9. Uncontrolled hypertension.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA
Recruitment hospital [1] 0 0
Flinders Medical Centre, Dept. of Oncology - Bedford Park
Recruitment postcode(s) [1] 0 0
- Bedford Park
Recruitment outside Australia
Country [1] 0 0
Belgium
State/province [1] 0 0
Antwerp
Country [2] 0 0
Belgium
State/province [2] 0 0
Brussels
Country [3] 0 0
Belgium
State/province [3] 0 0
Charleroi
Country [4] 0 0
Belgium
State/province [4] 0 0
Gent
Country [5] 0 0
Belgium
State/province [5] 0 0
Leuven
Country [6] 0 0
Belgium
State/province [6] 0 0
Liège
Country [7] 0 0
Germany
State/province [7] 0 0
Niedersachsen
Country [8] 0 0
Italy
State/province [8] 0 0
Ancona
Country [9] 0 0
Italy
State/province [9] 0 0
Genova
Country [10] 0 0
Italy
State/province [10] 0 0
Milano
Country [11] 0 0
Spain
State/province [11] 0 0
Barcelona
Country [12] 0 0
Spain
State/province [12] 0 0
Santander
Country [13] 0 0
Spain
State/province [13] 0 0
Valencia
Country [14] 0 0
Sweden
State/province [14] 0 0
Gothenburg
Country [15] 0 0
Sweden
State/province [15] 0 0
Stockholm
Country [16] 0 0
Sweden
State/province [16] 0 0
Uppsala

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Celgene Corporation
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to determine whether lenalidomide in combination with cetuximab
is safe and effective in patients with KRAS mutant colorectal cancer.
Trial website
https://clinicaltrials.gov/show/NCT01032291
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Eric Van Cutsem, M.D., Ph,D
Address 0 0
Universitaire Ziekenhuis Gasthuisberg K.U. Leuven, Belgium
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries